{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-24-011573","form_type":"8-K","ticker":"MNPR","cik":"0001645469","company_name":"Monopar Therapeutics","filed_at":"2024-04-10T23:59:59+00:00","discovered_at":"2026-05-14T18:03:19.406622+00:00","generated_at":"2026-06-04T00:25:50.294562+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Monopar initiates Phase 1 dosimetry trial for MNPR-101-Zr in advanced cancers","bullets":["Trial open for enrollment at Melbourne Theranostic Innovation Centre; led by Prof. Rodney Hicks.","Evaluating safety/dosimetry in up to 12 advanced cancer patients using total-body PET/CT scanner.","MNPR-101 targets uPAR expressed on pancreatic, breast, colorectal, and bladder tumors.","Preclinical data show specific tumor uptake; if Phase 1 positive, plan to test MNPR-101 with therapeutic Ac-225."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-24-011573","json":"https://secwatch.observer/filing/0001437749-24-011573.json","markdown":"https://secwatch.observer/filing/0001437749-24-011573.md","text":"https://secwatch.observer/filing/0001437749-24-011573.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1645469/000143774924011573/0001437749-24-011573-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1645469/000143774924011573/mnpr20240402_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-04T00:25:50.294562+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}